{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 29,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "The chart shows dose-response curves where LNC formulations consistently outperform Taxol.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/21",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.45,
        "y": 0.33
      },
      "kind": "chart",
      "text": "Line chart showing % Inhibition vs LNC-Docetaxel Dose (ng/well) for MM-51, MM-53, MM-54, and Taxol.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6047fc5c-db25-4d14-aece-627f89d6fb96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.06,
        "y": 0.36
      },
      "kind": "list",
      "text": "LNC Docetaxel program also provides insight into tumor uptake of LNCs; Foundation for subsequent small oligo work; In vitro results demonstrate strong LNC efficacy in inhibiting tumor cell growth; In vivo studies planned in multiple tumor models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5e8d630-8f60-4858-b719-4362a0b484da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.37,
        "y": 0.87
      },
      "kind": "paragraph",
      "text": "MCF7 breast cancer cells",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2065e1bb-970e-4ea7-ad3d-c925816f594f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.53,
        "y": 0.21
      },
      "kind": "title",
      "text": "3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92c5c6b-d70b-4300-9786-9ae17fc26ddf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39daa6ed-1a6f-41fd-8a64-da2545b3b170",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}